UA52191A - Способ лечения туберкулезного менингоэнцефалита - Google Patents
Способ лечения туберкулезного менингоэнцефалита Download PDFInfo
- Publication number
- UA52191A UA52191A UA2002032005A UA200232005A UA52191A UA 52191 A UA52191 A UA 52191A UA 2002032005 A UA2002032005 A UA 2002032005A UA 200232005 A UA200232005 A UA 200232005A UA 52191 A UA52191 A UA 52191A
- Authority
- UA
- Ukraine
- Prior art keywords
- meningoencephalitis
- tuberculous
- patients
- day
- ethambutol
- Prior art date
Links
- 206010014599 encephalitis Diseases 0.000 title claims abstract description 22
- 201000011475 meningoencephalitis Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 22
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims abstract description 42
- 229960000285 ethambutol Drugs 0.000 claims abstract description 21
- 230000001355 anti-mycobacterial effect Effects 0.000 claims abstract description 14
- 239000006215 rectal suppository Substances 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims description 18
- 239000002831 pharmacologic agent Substances 0.000 claims description 7
- 238000012876 topography Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 14
- 229940079593 drug Drugs 0.000 abstract description 13
- 239000003926 antimycobacterial agent Substances 0.000 abstract description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 18
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 9
- 229960003350 isoniazid Drugs 0.000 description 9
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 9
- 229960005322 streptomycin Drugs 0.000 description 9
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 8
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 6
- 229960001225 rifampicin Drugs 0.000 description 6
- 239000000829 suppository Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000008827 tuberculosis Diseases 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229960005206 pyrazinamide Drugs 0.000 description 5
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 5
- 230000035987 intoxication Effects 0.000 description 4
- 231100000566 intoxication Toxicity 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 description 3
- -1 benamycin Chemical compound 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 229960002001 ethionamide Drugs 0.000 description 3
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000252 mycobacteriostatic effect Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960000918 protionamide Drugs 0.000 description 3
- 206010010071 Coma Diseases 0.000 description 2
- 208000012766 Growth delay Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 206010053759 Growth retardation Diseases 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010058709 Sopor Diseases 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ лечения туберкулезного менингоэнцефалита состоит в применении фармакологических средств противомикобактериального действия и применении этамбутола в ректальных суппозиториях. Каждый из противомикобактериальных препаратов применяют в суточной дозе однократно равномерно на протяжении суток.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002032005A UA52191A (ru) | 2002-03-12 | 2002-03-12 | Способ лечения туберкулезного менингоэнцефалита |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UA2002032005A UA52191A (ru) | 2002-03-12 | 2002-03-12 | Способ лечения туберкулезного менингоэнцефалита |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA52191A true UA52191A (ru) | 2002-12-16 |
Family
ID=74284502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002032005A UA52191A (ru) | 2002-03-12 | 2002-03-12 | Способ лечения туберкулезного менингоэнцефалита |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA52191A (ru) |
-
2002
- 2002-03-12 UA UA2002032005A patent/UA52191A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoehn-Saric et al. | Effects of clonidine on anxiety disorders | |
| McDowell et al. | Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa) | |
| SUGERMAN et al. | Haloperidol in the psychiatric disorders of old age | |
| Shubin et al. | Bacterial shock: A serious complication in urological practice | |
| Field et al. | Antibiotic treatment of epidemic bronchiolitis--a double-blind trial | |
| Nisijima et al. | Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases | |
| JPS62106015A (ja) | 抗痴呆薬 | |
| Nugent et al. | Glucocorticoid toxicity: single contrasted with divided daily doses of prednisolone | |
| McElroy et al. | Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania | |
| Sloane et al. | The use of imipramine (tofranil) for depressive states in open ward settings of a general hospital: a preliminary report | |
| BARSA et al. | Amitriptyline (Elavil), a new antidepressant | |
| Doraiswamy et al. | Anticholinergic drugs and elderly people: a no brainer? | |
| Lee et al. | Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent | |
| Collins et al. | A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics | |
| Winner et al. | Guillain-Barré syndrome in Oxfordshire: clinical features in relation to age | |
| KR20230050363A (ko) | 질환의 치료에 있어서 btk 저해제의 용도 | |
| Boellner et al. | Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study | |
| UA52191A (ru) | Способ лечения туберкулезного менингоэнцефалита | |
| JUDAH et al. | Psychiatric response of geriatric-psychiatric patients to Mellaril (TP-21 Sandoz) | |
| Montgomery et al. | Acute dystonic reaction to perphenazine | |
| Plaut et al. | Toxic epidermal necrolysis due to E coli | |
| CN111065389A (zh) | 治疗自身免疫性微脉管疾病的方法 | |
| CRANNY et al. | The Use of Hydrocortisone in the Treatment of Tuberculous Meningitis: A Study of Steroid Concentrations in Cerebrospinal Fluid | |
| Godwin-Austen et al. | Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa | |
| Symes | Monochlorimipramine: a controlled trial of a new antidepressant |